Fewer, Larger Radiotherapy Doses Prove Effective for Prostate Cancer Patients

Giving fewer but higher doses of radiotherapy (RT) is as effective at treating prostate cancer as giving lower doses for a longer period, according to new research presented at the 2015 European Cancer Congress. The results could mean men need fewer trips to the hospital over four weeks (rather than seven and one-half) without reducing the quality and impact of their prostate cancer treatment.

The Cancer Research UK funded CHHiP trial – the largest randomized treatment trial ever undertaken in localized prostate cancer led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust – gave 3,216 men with prostate cancer from across the UK different schedules of RT. Some men received standard RT of 74 Gray (Gy) over 37 days (two Gy a day) while others were given either 60 Gy delivered over 20 days or 57 Gy over 19 days (three Gy a day).

The researchers then followed these men for five years and, overall, found that giving patients 60 Gy over 20 days was as effective as the standard treatment – in terms of both controlling the disease and for long-term side effects. Some short-term side effects of the higher daily RT doses during and immediately after RT were higher than for standard RT, but these – including bowel and bladder problems – were not long lasting. There was no difference in the side effects after six months or during the next five years.

Lead investigator Professor David Dearnaley, professor of uro-

Study Raises Questions about Androgen Deprivation for Certain Prostate Cancer Cases

Men with unfavorable-risk prostate cancer and moderate or severe comorbidities had significantly decreased overall and cardiac mortality when treated with radiotherapy (RT) alone vs. RT and androgen deprivation therapy (ADT), according to a study described in a research letter in JAMA. In the letter, D’Amico et al present long-term follow-up to their 2008 randomized trial that showed that six months of ADT + RT vs. RT alone prolongs survival and is the standard treatment for unfavorable-risk prostate cancer.

The new findings build on a recent analysis of a randomized controlled trial of four trials with 1,774 men (HR 0.94). Treatment duration and off-treatment periods varied widely across the studies, however, and the criteria for stopping and restarting therapy varied as well. And as reported online in JAMA Oncology on Septem-

(Continued on page 6)
ED Induced by Prostate Biopsy Likely 'Underestimated'

The various degrees of erectile dysfunction (ED) that occur after prostate biopsy with a needle through the rectum wall have probably been underestimated, according to a new research published in the August issue of BJU International (Vol. 116, p. 164, 2015).

A new study showed a significant decrease in the erectile function (EF) score of most men after biopsy, and the drop was independent of age, cancer diagnosis, and previous biopsy status, report the study authors, led by Katie Murray, MD, from the University of Kansas Medical Center in Kansas City. Although ED was recognized as a complication of prostate biopsy as early as 2001, it has not been well-established by data, unlike potential adverse events such as hematuria, pain, voiding dysfunction, and infection.

In their prospective study, Dr. Murray and her team used a standard test—the International Index of Erectile Function (IIEF-5)—to evaluate 220 men with elevated levels of PSA who underwent a transrectal-ultrasound-guided prostate biopsy. In the study cohort, median IIEF-5 score was significantly lower one week after biopsy than at baseline (15.5 vs. 18.2; $P < 0.001$). And the score remained significantly lower at four weeks (17.3 vs. 18.4; $P = 0.008$) and 12 weeks (16.9 vs. 18.4; $P = 0.004$). The team does not, however, say that the needle caused physical damage in this nerve-intensive area that led to ED. "The exact cause of this effect is yet to be determined," they write.

"Psychological stress" likely contributes to the ED, writes Brian Helfand, MD, from the University of Chicago, in an accompanying editorial. The men in this study who had a benign biopsy had a fairly quick return to baseline in terms of their EF (after one week, as a group), even though some men reported lower scores for up to three weeks. Dr. Helfand points out that a study he was previously involved in showed that a diagnosis of prostate cancer "can influence a man's erectile function after prostate biopsy."

"The literature on this subject is mixed, with some studies finding and some not finding that biopsy induces ED," he adds. Nevertheless, Dr. Helfand suggests that "patients should be counseled on the possibility of relatively short-term ('acute') changes in EF." Dr. Murray and her team say the same thing.

"This single-group study could have been stronger in terms of its evidence," said Clint Bahler, MD, from Indiana University in Indianapolis, who was not involved in the study but was asked to comment on the findings. "They should have followed another group of [healthy] men with elevated PSA who did not get biopsy to compare, for instance," he told Medscape Medical News. Like Dr. Helfand, Dr. Bahler pointed out that men who had a benign biopsy (67% of the group) had relatively transient ED, compared with those who had cancer detected.

For the men who did not get a diagnosis of prostate cancer, median IIEF-5 score was lower only at the one-week follow-up ($P = 0.015$). But for men 60 years and older, scores were lower at one week ($P < 0.001$), four weeks ($P = 0.024$), and 12 weeks ($P = 0.005$).

The investigators also used the International Prostate Symptom Score (IPSS) questionnaire to evaluate the men. They focused on data related to lower urinary tract symptoms, and found that there was a significant change at weeks one and four, but not at week 12. In other words, in this cohort of men, symptoms, on average, improved by week 12.

Medscape Medical News 1 October 2015
Doc Moyad’s What Works & What is Worthless Column, Also Known As “No Bogus Science” Column – “Buongiomo! Drinking coffee in Italy - the Moyad experience & More!”
Mark A. Moyad, MD, MPH, University of Michigan Medical Center, Department of Urology
Editor’s Note:
Us TOO invites certain physicians and others to provide information and commentary for the Hot SHEET to enrich its content to empower the reader. This column contains the opinions and thoughts of its author and are not necessarily those of Us TOO International.

**Bottom Line:**
A major colon cancer clinical study and now multiple prostate cancer studies are beginning to suggest that coffee could have anti-cancer properties! 

I just returned a few hours ago from a brief working trip that took me through Southern Italy (I know... life is real harsh at times, but someone has to be Mark Moyad). And, now I am semi-addicted to coffee because in Italy it is ubiquitous, and you can’t escape from it, which is kind of like those attorney ads on TV or on the highway in the US that promise you that you will get paid big money for suing someone or something. Espresso, cappuccino, café Americano... I learned about all of them by trying all of them (again someone has to be me). And apart from the fact that I had more energy than a five-year old kid after eating a box of sugar, it was incredible that I saw no one use a “to go” cup or simply walk down the street drinking coffee – not a single person in any of the cities I visited? What the heck is going on?

These Italians stand or sit in a café and drink and talk and then move on. Perhaps it is not the coffee but the underlying comprehensive healthy behavior of the coffee drinker in some of these countries. They appear to regularly socialize, relax, remain strong spiritually, walk constantly, and eat very healthy diets but only in small to moderate portions. For example, I ordered a crab-stuffed ravioli in Rome, a pizza in Naples, Caprese salad in Sorrento, and anchovies in Amalfi that I swear in every case would never even qualify as an appetizer (“antipasti”) in the US, and each single item was considered one full-meal in Italy! This must be the secret (or my continuous IV olive oil pump)! On the other hand, multiple new human studies are also suggesting that coffee (especially the low- or no-calorie caffeinated type) itself has some anti-cancer/anti-inflammatory properties and could reduce insulin over-exposure, which means not only as a preventive but as a way to reduce cancer recurrence. 

**Mutation Predicts Poor Chemotherapy Outcome**

The presence of the TMPRSS2-ERG mutation in blood may predict how well patients with metastatic castration-resistant prostate cancer (mCRPC) respond to docetaxel, according to study findings presented at the 2015 European Cancer Congress (ECC) in Vienna, Austria. Óscar Reig, MD, of Hospital Clinic, Barcelona, Spain, and colleagues prospectively evaluated TMPRSS2-ERG in peripheral blood mononuclear cells (PBMC) in 50 men with mCRPC treated with docetaxel. Men with TMPRSS2-ERG had a significantly lower rate of PSA response to docetaxel compared with those who did not have TMPRSS2-ERG (12.5% vs. 68.3%). They also had a significantly lower median PSA progression-free survival (PFS) (3.1 vs. 7.5 months), and lower median clinical/radiologic PFS (3.1 vs. 8.2 months). In multivariate analysis, TMPRSS2-ERG was independently associated with a 3.7 and 6.3 times higher risk of PSA progression and clinical/radiologic progression, respectively (P <0.05).

“TMPRSS2-ERG predicts [a] low response rate to docetaxel and poor outcome in mCRPC patients,” the authors concluded in a study abstract. “These data support its potential role as a biomarker to tailor treatment strategy.”

**Silicon and Bone Health**

Rodella LF, Bonazza V, Labanca M, et al

J Nutr Health and Aging 2014; 18: 820-826

**Objective:**
Increasing evidences suggest that dietary silicon intake is positively correlated with bone homeostasis and regeneration representing a potential and valid support for the prevention and improvement of bone diseases like osteoporosis. This review aims to provide the state of art of the studies performed until today in order to investigate and clarify the beneficial properties and effects of silicates on bone metabolism.

**Methods:**
We conducted a systematic literature search up to March 2013, using two medical databases (PubMed and the Cochrane Library), to review the studies about silicon consumption and bone metabolism.

**Results:**
We found 45 articles, but 38 were specifically focused on silicon studies.

**Conclusion:**
Results of this search showed a positive relationship between dietary silicon intake and bone regeneration.
Higher RT Doses Less Often (Continued from page 1)

“...These results are great news for men. From a logistical and patient convenience point of view, being able to treat men over a shorter period of time has been a goal for specialists, but the question has always been whether it was safe to do so. This study shows that it is safe and effective, and there should be no reason why this cannot be implemented immediately – it is saving the NHS resources.”

He continued, “But there are still questions that need answers. It’s not impossible that fewer, but bigger fractions of RT might be still better at controlling the disease, but this would need more data from large clinical trials to answer. We look forward to seeing more research – perhaps by combining this and similar studies. It’s also valuable to see the impact of the shorter treatment on side effects. Reassuringly, these are no different to the older, standard treatment.”

Adapted by Medical News Today 28 September 2015

Impact of the CCP Test on Physician and Patient Treatment Selection for Localized PCa

Shore ND, Kella N, Moran B, et al

J Urol 21 September 2015; Epub

Purpose: The CCP test is a validated molecular assay that assesses prostate cancer-specific disease progression and mortality risk when combined with clinicopathologic parameters. The results from PROCEED-1000, a large, prospective registry designed to evaluate the impact of the CCP test regarding shared treatment decision making for newly diagnosed prostate cancer patients, are presented here.

Materials and Methods: Untreated patients with newly diagnosed prostate adenocarcinoma were enrolled and the CCP test was performed on the initial prostate biopsy tissue. A set of four sequential surveys tracked changes relative to initial therapy recommendations (pre-CCP) based on clinicopathologic parameters following: physician review of the CCP test result, physician/patient review of the CCP test results, and a minimum of three-months of clinical follow-up (actual treatment).

Results: 1,206/1,596 patients enrolled in this registry were eligible for analysis. There was a significant reduction in the treatment burden recorded at each successive evaluation (P <0.0001), with mean number of treatments per patient decreases from 7.7 to 3.5. Prevalence of inappropriate prostate cancer imaging was 33 percent and 13 percent at the initial treatment decision and 27 percent and 5 percent at each successive evaluation, respectively, with a significant decrease in the subopimal rates of imaging with each successive evaluation (P <0.0001). Veterans with high-risk disease were less likely to undergo inappropriate imaging compared to lower-risk disease (OR: 0.50 0.46-0.54) and subopimal rates of imaging with each successive evaluation (P <0.0001).

Conclusions: Our results highlight the overutilization of imaging, even in an integrated health care system without financial incentives encouraging provision of health care services. Paradoxically, imaging remains underutilized among high-risk patients who could potentially benefit from it most.

Prostate Cancer Diagnoses Drop after USPSTF ‘Don’t Screen’ Recommendation

Prostate cancer diagnoses decreased by 28 percent in the first year following the US Preventive Services Task Force (USPSTF) recommendation against regular PSA screening, according to a new analysis published online September 22nd in the Journal of Urology. Diagnoses of low-, intermediate-, and high-risk prostate cancers declined significantly during that period, although new diagnoses of nonlocalized disease did not change.

“It is not surprising that new diagnoses of nonlocalized disease have remained the same,” explained lead author Daniel A. Barocas, MD, MPH, of the Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN. “Our data go to 2012, so it’s really only a year since the guideline was issued,” he said. “I would have not expected to see a change at this point in time.”

In October 2011, the USPSTF recommended against routine screening for prostate cancer using the PSA test, which has caused considerable controversy among professional organizations, patient advocacy groups, and physicians. Prior to this, the USPSTF had already recommended against routine PSA screening in men older than 75 years, but the new guidelines...
Exploiting Altered Patterns of Choline Kinase-alpha Expression on Human Prostate Tissue to Prognosticate Prostate Cancer
Challapalli A, Trousil S, Hazell S, et al
J Clin Pathol 2015; 68: 703-709

Aims: Malignant transformation results in overexpression of choline-kinase (CHK) and altered choline metabolism, which is potentially detectable by immunohistochemistry (IHC). We investigated the utility of CHK-alpha (CHKA) IHC as a complement to current diagnostic investigation of prostate cancer by analysing expression patterns in normal (no evidence of malignancy) and malignant human prostate tissue samples.

Methods: As an initial validation, paraffin-embedded prostatectomy specimen blocks with both normal and malignant prostate tissue were analysed for CHKA protein and mRNA expression by western blot and quantitative reverse transcriptase PCR (qRT-PCR), respectively. Subsequently, 100 paraffin-embedded malignant prostate tumour and 25 normal prostate cores were stained for both Ki67 (labelling-index: LI) and CHKA expression.

Results: The validity of CHKA-antibody was verified using CHKA-transfected cells and siRNA knockdown. Immunoblotting of tissues showed good resolution of CHKA protein in malignant prostate, verifying use of the antibody for IHC. Minimal CHKA mRNA was detected by qRT-PCR in normal tissue; conversely high expression in malignant prostate tissues. IHC of normal prostate cores showed mild CHKA expression in only 28% (7/25) of samples with no Ki67 expression. In contrast, CHKA was expressed in all malignant prostate cores along with characteristically low proliferation (median 2% Ki67-LI; range 1–17%). Stratification of survival according to CHKA intensity showed a trend towards lower progression-free survival with CHK score of 3.

Conclusions: Increased expression of CHKA, detectable by IHC, is seen in malignant lesions. This relatively simple cost-effective technique (IHC) could complement current diagnostic procedures for prostate cancer and, therefore, warrants further investigation.

RT + ADT in Prostate Cancer Patients with Comorbidity (Continued from page 1)

six months of ADT at three academic and three community-based centers in Massachusetts between 1995 and 2001. At a median follow-up of 16.6 years, 156 (76%) men died; 29 (19%) died of prostate cancer, 39 (25%) of cardiac causes, and 88 (56%) of other causes.

Among men with moderate or severe comorbidity, 46/49 (94%) had died compared to 110/157 (70%) men with no or minimal comorbidity. Survival did not differ in the men receiving RT alone vs. those receiving RT + ADT, “but opposite effects of treatment on survival were observed in the comorbidity subgroups,” the authors reported.

In multivariable analyses, RT alone vs. RT + ADT in men with no or minimal comorbidity was associated with significantly increased overall mortality (hazard ratio [HR] 1.5, 95% CI 1.0-2.2, P = 0.04) and prostate cancer mortality (HR 4.3, 95% CI 1.6-11.5, P = 0.004), no difference in cardiac mortality (HR 1.7, 95% CI 0.6-4.6, P = 0.28), and decreased other-cause mortality (HR 0.6, 95% CI 0.4-1.0, P = 0.04).

Conversely, in men with moderate or severe comorbidity, RT alone vs. RT + ADT was associated with significantly decreased overall mortality (HR 0.4, 95% CI 0.2-0.7, P = 0.001) and cardiac mortality (HR 0.2, 95% CI 0.1-0.5, P <0.001).

This finding is in contrast to no association with overall mortality at a median follow-up of 7.6 years, as previously reported. In addition, among men with moderate or severe comorbidity, RT alone was associated with no difference in prostate cancer mortality, and increased other-cause mortality.

“The results are hypothesis-generating and require validation,” D’Amico said. Nevertheless, the association of treatment with RT alone with decreased cardiac and overall mortality in men with moderate or severe comorbidity suggests that administering ADT to treat unfavorable-risk prostate cancer in these men should be carefully considered.”

The ASCO Post
22 September 2015

A Phase II Randomized Trial of Lycopene-Rich Tomato Extract Among Men with High-Grade Prostatic Intraepithelial Neoplasia
Gann PH, Deaton RJ, Rueter EE, et al
Nutr Cancer 13 October 2015; Epub

A diverse body of evidence suggests that lycopene might inhibit prostate cancer development. We conducted a six-month repeat biopsy randomized trial among men with high-grade prostatic intraepithelial neoplasia (HGPIN).

Here we report results for serum lycopene, prostate specific antigen (PSA) and insulin-like growth factor (IGF) proteins, histopathological review, and tissue markers for proliferation minichromosome-some maintenance protein 2 (MCM-2]) and cell cycle inhibition (p27). Participants consumed placebo or tomato extract capsules containing 30 mg/day lycopene. Pre- and post-treatment biopsies were immunostained and digitally scored. Serum lycopene was determined by LC-MS-MS. In secondary analyses, pathologists blindly reviewed each biopsy to score histological features. Fifty-eight men completed the trial. Serum lycopene increased by 0.55 μmol/L with treatment and declined 0.29 μmol/L with placebo. We observed no meaningful differences in PSA, IGF-1, or IGF binding protein 3 concentrations between groups, nor any differences in expression of MCM-2 or p27 in epithelial nuclei. Prevalences of cancer, HGPIN, atrophy, or inflammation posttreatment were similar; however, more extensive atrophy and less extensive HGPIN was more common in the lycopene group. Despite large differences in serum lycopene following intervention, no treatment effects were apparent on either the serum or benign tissue endpoints. Larger studies are warranted to determine whether changes observed in extent of HGPIN and focal atrophy can be replicated.
Prostate Cancer Diagnoses Drop after USPSTF Recommendation

(Continued from page 4)

extended it to all men. PSA testing was given a “D” rating, which means “there is moderate or high certainty that the service has no benefit or that the harms outweigh the benefits.”

Some of the effects of this guideline may be beneficial in terms of reducing harms related to overdiagnosis and overtreatment, Dr. Barocas told Medscape Medical News. “But not only are we missing low-risk diagnoses, we are also missing diagnoses of intermediate- and high-risk disease. A delay in the diagnosis for those patients could lead to worse outcomes.”

Previous research has suggested that higher-risk disease could be on the rise because of the decline in screening. One study found that the rate of higher-risk prostate cancer rose slightly but significantly in the United States during 2011 and 2012. The 3% increase in each of those two years coincides with the changes that were made in USPSTF prostate cancer guidelines in 2009 and 2011. Without screening, many of these cancers will not be detected until they are advanced. Dr. Barocas continued, “Patients are generally not symptomatic until the disease is more advanced and may be difficult to treat.” But even one year after the recommendations, he noted that they were already seeing reductions in the diagnosis of intermediate- and low-risk disease. “We saw an almost 30% reduction in the diagnosis of intermediate prostate cancer,” he said. “A decline of that magnitude is huge. This shows that we are missing important opportunities to treat these men with curative therapies.” As time goes on, the full impact of the guidelines will become more apparent. “In a year or two, we will have a better idea of the impact that they are having, especially in men with high-risk disease,” Dr. Barocas said.

Using data from the National Cancer Database, the authors sought to determine whether the number of incident cases of prostate cancer per month has substantially changed since the guideline. They assessed the trend of new prostate cancer cases that were diagnosed each month before and after the draft guideline. The bulk of new cases were diagnosed in men between the ages of 60 and 69 years (43.7%), and the majority were white (80%). There was a small predominance of intermediate-risk disease in localized cases as compared with low- and high-risk disease (32.2% vs. 25.4% vs. 27.0%); 5.4% of men had nonlocalized disease at diagnosis. Prior to the introduction of the guideline, the number of monthly diagnoses of prostate cancer ranged from 9,442 to 12,021, and diagnoses were increasing by approximately 45 cases per month (0.4%). In October 2011, however, there was a significant and immediate reduction in estimated diagnoses of incident disease of -3.73% cases, along with a significant change in trend in the periods before and after the guidelines were issued. This represented a relative decrease of 164 cases per month, corresponding to a change of -12.2% (P <0.01) in incidence in the month that immediately followed the publication of the guidelines. After that, there was an ongoing rate of decrease of -1.8% per month (P <0.01).

A year after its release, the number of new diagnoses had declined by 27.9% as compared with the projected trend from the period before the guideline was issued. When looking at the different subgroups, diagnoses declined in all risk categories. Monthly diagnoses initially decreased -16.9% for low-risk, -12.9% for intermediate-risk, -10.1% for high-risk, and -2.7% for nonlocalized disease. The corresponding monthly changes thereafter were -2.7, -1.9, -1.4 and -0.1%, respectively (P-interaction <0.01).

“This study clearly shows how important it is to utilize PSA for appropriately managing various stages of prostate cancer, including initial diagnosis, and to avoid overutilization,” commented Khurshid Guru, MD, associate Professor of oncology in the Department of Urology at Roswell Park Cancer Institute, Buffalo, New York, who was approached by Medscape Medical News for an independent comment.

Dr. Barocas and his colleagues agree. They call for more research that focuses on screening paradigms that will minimize harms but at the same time maximize the potential benefits of screening and take into account individual patient risk factors and preference.

Medscape Medical News
22 September 2015

No Bogus Science
(Continued from page 3)

References:
Improvements in radiation therapy techniques are making it possible to deliver higher doses of radiation per dose thereby completing the therapy in a shorter amount of time. What remains unknown so far is whether the long-term survival rates will be at least as good as the conventional approach. Early results of an ongoing randomized trial comparing the standard 37 treatments to 19 or 20 were recently presented at the European Cancer Congress. The investigators reported similar long-term toxicity and similar rates of disease progression. Important issues for readers to note are that the patients did receive hormone therapy, it included an undefined number of low-risk patients, and this was a pilot trial, not designed to assess long-term survival. Details of the study can be reviewed at [https://clinicaltrials.gov/ct2/show/NCT00392535](https://clinicaltrials.gov/ct2/show/NCT00392535). That means it is still too early to know for certain if the shorter course of therapy is better for patients but hopefully that study will be forthcoming. The Bottom Line: Early results suggest that 19 or 20 days of XRT may be as good as the standard 37 days but more work is needed before that conclusion can be made.

The technique of meta-analysis has been suggested as a way to combine the results from several randomized studies in which the outcomes were inconsistent. The idea is that by increasing the number of patients under evaluation, the ability to detect small but significant differences in outcome is increased. That technique was used in a large number of studies assessing the impact of continuous vs. intermittent androgen deprivation therapy (ADT) in men with treated or untreated prostate cancer. The authors acknowledge a high likelihood of bias in all but one of the studies. What kinds of problems may have occurred that could limit the reliability of the results? First, the studies did not evaluate homogeneous groups of patients. For example, some men had recurrent disease and some had never received local therapy. Combining them into a single group requires a careful assessment that the groups behave similarly and it is unclear if the authors did it. Another problem is that the method for intermittent ADT is not standardized. Readers of the Hot SHEET should always be on the alert when they read the results of a meta-analysis because it is very easy to reach incorrect conclusions.

The Bottom Line: This meta-analysis does not prove that intermittent ADT is equivalent to continuous therapy.

When the USPTF accumulated its data evaluating the risks and benefits of screening with PSA, they weighed the potential risks against the potential benefits. Ultimately, they reached the conclusion that the harms outweighed the benefits. Potentially, the study by Murray et al might have added fuel to the downside impact of screening. In this study, the authors suggest that men undergoing a prostate biopsy had a decrease in sexual function up to 12 weeks later. But the results differed according to the patient’s age with the younger men recovering very quickly. Although this study was randomized, several factors were lacking as pointed out by the two commentaries accompanying the article. First, the authors did not assess changes in a comparable cohort of men who did not undergo a biopsy. Second, the results were markedly different in the men diagnosed with prostate cancer vs. those without cancer. The latter group only had a decrease in their sexual function questionnaire at one week but no difference at 12 weeks. A third factor not mentioned by the commentators was whether the results varied depending on the initial IEFF score. It is possible that change in IEFF score was dependent on the initial score, meaning that men with a score above a certain number had different effect than those below that number. Lastly, even if a difference is real, it is completely unclear whether the effect was caused by a psychological change after a man was given a diagnosis of prostate cancer. It would have been helpful to know if all the men were informed of their biopsy results before the one-week assessment began.

The Bottom Line: More work is needed to know whether a prostate biopsy truly has a negative short-term impact on erectile function, and if that is true, why that occurs.

One of the most important challenges in cancer therapy is trying to understand why some individuals respond to a particular therapy and others do not. If that could be answered, individualized treatments could be given to men most likely to respond while avoiding treatments for men least likely to respond thereby avoiding wasted time and money. The study by Reig and co-workers shows promise as a way to identify which men should or should not receive docetaxel chemotherapy. They measured TMPRSS2-ERG mutation in blood of men with metastatic castration resistant disease and found that those men who had the mutation did not respond well to the chemotherapy. This information could be used to lower cost and patient morbidity. Hopefully other important markers will become available in the near future that will enhance the ability of doctors to tailor therapy that is more effective.

The Bottom Line: A mutation of TMPRSS2-ERG may become an important method for identifying which men should not receive docetaxel therapy when their cancer has progressed.

Impact of CCP Test (Continued from page 4)

Increasing from 1.72 pre-CCP test to 1.16 in actual follow-up. The CCP test caused a change in actual treatment in 47.8% of patients. Of these changes, 72.1% were reductions and 26.9% were increases in treatment. For each clinical risk category, there was a significant change in treatment modality (intervention vs. non-intervention) pre-CCP to post-CCP testing (P = 0.0002).

Conclusions: The CCP test has a significant impact in assisting physicians and patients reach personalized treatment decisions.
Testosterone Levels Improve in Obese Men Following a Common Weight-Loss Operation

A common weight-loss operation called sleeve gastrectomy can make testosterone levels normal in obese men, according to new findings presented at the 2015 Clinical Congress of the American College of Surgeons. Surgeons from Stanford University in California reported that after undergoing this bariatric surgical procedure, obese patients with low testosterone levels experienced a measureable increase in their testosterone levels over a 12 month-period following the operation.

“When men are obese, they have low testosterone. Low testosterone is known to impact sexual quality of life, but it’s also an independent cardiac risk factor. Men with low testosterone have more cardiac events than men with normal testosterone,” according to study coauthor John Morton, MD, MPH, FACS, chief, bariatric and minimally invasive surgery, Stanford University School of Medicine. “Low testosterone also increases the risk of sarcopenia, a loss of muscle that accelerates the aging process, so it has an impact on many different levels.”

The aim of the study was to investigate the effects of surgical weight loss following sleeve gastrectomy on serum testosterone, DHEA (a precursor to testosterone), and PSA. This clinical study involved 24 obese male patients undergoing gastric sleeve surgery, also called sleeve gastrectomy, at Stanford Hospital. Serum testosterone, DHEA, and PSA were measured before and at three, six, and 12 months after the procedure.

The researchers found that the study group experienced a significant increase in average serum testosterone after undergoing sleeve gastrectomy. At 12 months, testosterone had increased on average from 295 to 423 ng/dL. The normal range for circulating testosterone is 300 to 1000 ng/dL. A person is diagnosed with low serum testosterone when the level drops below 300 ng/dL.

Before the procedure, 63 percent of participants had low testosterone and afterwards, only 41 percent did. The average BMI was 46 before surgery and 31 after the operation. In addition, DHEA also rose, from 12.8 to 39.6 ng/mL, and serum PSA concentration rose over 12 months from 0.62 to 0.75 ng/mL with no change in PSA mass, which is a marker for prostate cancer progression.

More men should seek surgical care for obesity as they carry more risk from their weight—low testosterone causes further weight gain, increases cardiac risk, and decreases quality of life. And sleeve gastrectomy can improve all of those comorbidities,” Dr. Morton said.

Sleeve gastrectomy has never been studied in this way before. Sleeve gastrectomy, which was introduced about 10 years ago, has replaced gastric bypass as the new gold standard in weight-loss operations. It’s a shorter, lower-risk procedure.

“When you are obese, your fat becomes converted to estrogen, which will compete with testosterone and drive it down,” Dr. Morton said. “When patients are losing weight, they lose that estrogen, which causes natural testosterone stores to rise.”

“The take home message is that if you are an obese man with low testosterone your therapy should be weight loss not testosterone replacement, and a successful way to achieve meaningful weight loss is through a bariatric operation,” Dr. Morton concluded.

Adapted by Medical News Today 6 October 2015